All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction
In patients with T2DM and HFrEF, GLP-1 RA therapy shows potential beneficial effects in reducing CV events over 5 years compared to control (DPP4i) group.
Authors
- Peter Oro (ORCID: https://orcid.org/0000-0003-2686-3632)
- Gautam Shah (ORCID: https://orcid.org/0009-0004-4791-4114)
- Joseph El Dahdah (ORCID: https://orcid.org/0000-0002-8480-3745)
- Amanda R. Vest (ORCID: https://orcid.org/0000-0001-8274-5660)
- Aravinthan Vignarajah (ORCID: https://orcid.org/0000-0002-3758-0024)
- Nishanthi Vigneswaramoorthy
Institutions
- Cleveland Clinic (US)
- SUNY Upstate Medical University (US)
- Upstate University Hospital (US)
- South Pointe Hospital (US)
Publication Details
- Journal
- American Heart Journal Plus Cardiology Research and Practice
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.ahjo.2025.100676
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29